Loading...
Abbisko Cayman Limited
2256.HK•HKSE
Healthcare
Biotechnology
HK$10.33
HK$-0.31(-2.91%)
Abbisko Cayman Limited (2256.HK) AI-Powered Stock Analysis
See how Abbisko Cayman Limited scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerAbbisko Cayman Limited (2256.HK) Stock Overall Grade
Abbisko Cayman Limited’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
B+
Good
Grade Breakdown by Metric
See how each financial and market factor contributes to Abbisko Cayman Limited's overall stock rating.
Forecast
BScore
64/100Financial Growth
A+Score
100/100Fundamental Growth
BScore
62/100Key Ratios
BScore
64/100Sector Comparison
B+Score
75/100Industry Comparison
B+Score
75/100S&P 500 Benchmark
AScore
85/100Analyst Consensus
C+Score
50/100Abbisko Cayman Limited (2256.HK) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 64/100 (B), reflecting high confidence in its potential. Financial Growth (100/100, A+) and Fundamental Growth (62/100, B) highlight its stability, while Key Ratios (64/100, B) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (85/100, A), it shows competitive strength. Analyst Consensus (50/100,C+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Abbisko Cayman Limited stock grade, including financials, comparisons, and forecasts.